CC
C4 Therapeutics, Inc.
CCCC · NASDAQ
$3.76 +1.08% (+$0.04)
1M +3.30%
Market Cap $413.5M
P/E Ratio -
Div. Yield -
ROE 45.45%
Piotroski F-Score Weak
3/9Valuation
48 /100
Fair P/B 1.67x
P/S 11.80x
PEG N/A
Growth
36 /100
Stable Book val. growth 3.91%
Rev. growth 4.95%
FCF growth N/A
Profitability
20 /100
Weak FCF margin 243.71%
Op. margin 318.97%
Gross margin 94.86%
Quality
1 /100
Poor Asset turnover 0.10x
ROA 28.22%
ROIC 35.21%
Debt
100 /100
Low Current ratio 5.45x
Debt/Equity 0.23x
Net debt/EBITDA N/A
Stability
25 /100
Unstable Profitable years 0
EPS volatility 22.62%
Beta 2.95x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na CCCC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Andrew J. Hirsch
Employees
104
Headquarters
Watertown
Nadcházející události
05 LIS
Earnings
Upcoming earnings report